Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | MMP3 | P08254 | 2/20 | 0.48 |
| ▸ | MMP7 | P09237 | 2/20 | 0.48 |
| ▸ | MMP9 | P14780 | 2/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29519352 | 0.88 | NPSR1 (0.51) | HTR2BGBA1MMP1MMP2MMP3 | |
| SCHEMBL171036 | 0.80 | KMT2A (0.61) | HTR2BALDH1A1KMT2A | |
| SCHEMBL8205185 | 0.79 | KMT2A (0.56) | GBA1PGRALDH1A1KAT6APSEN1 | |
| SCHEMBL532021 | 0.79 | HTR2B (0.47) | HTR2BALDH1A1CA2GFERNPSR1 | |
| SCHEMBL13623414 | 0.79 | PGR (0.53) | GBA1PGRALDH1A1KAT6ACA2 | |
| SCHEMBL12089569 | 0.79 | CA2 (0.51) | HTR2BPGRALDH1A1KAT6ACA2 | |
| SCHEMBL9866942 | 0.79 | HTR2B (0.49) | HTR2BALDH1A1GFERNPSR1 | |
| SCHEMBL12376750 | 0.79 | PGR (0.60) | HTR2BPGRALDH1A1 | |
| SCHEMBL265556 | 0.79 | HSD17B2 (0.49) | HTR2BMMP1MMP2MMP3MMP7 | |
| SCHEMBL3649156 | 0.79 | POLB (0.56) | HTR2BALDH1A1CA2KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145931-A1 | SMALL MOLECULE INHIBITOR FOR β-CATENIN/BCL9 PROTEIN-PROTEIN INTERACTION AND USE THEREOF | 上海医药工业研究院有限公司 | 2024-07-11 | — | — | WO | disclosed |
| US-20200039960-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20190144429-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2019-05-16 | — | — | US | disclosed |
| EP-3428160-A1 | HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF | Pfizer Inc (US) | 2019-01-16 | — | — | EP | disclosed |
| US-20180086736-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086736-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER (US) | 2016-02-18 | — | — | US | disclosed |
| US-8809264-B2 | Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| WO-2008021733-A2 | TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008019266-A2 | ACYCLIC, PYRIDAZINONE-DERIVED HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| US-20080038225-A1 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080038225-A1 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038225-A1 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, CTSC | HTR2B 2624/4885GBA1 716/4885MMP1 838/4885 |
| US-20200039960-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | HTR2B 3445/4885GBA1 3374/4885MMP1 2710/4885 |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | HTR2B 3445/4885GBA1 3374/4885MMP1 2710/4885 |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | HTR2B 3325/4885GBA1 465/4885MMP1 855/4885 |
| US-20180086736-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | HTR2B 3445/4885GBA1 3374/4885MMP1 2710/4885 |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | PRSS1, SPINT2, CTSC | HTR2B 3525/4885GBA1 448/4885MMP1 871/4885 |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1A, TUBA1C | HTR2B 3284/4885GBA1 1908/4885MMP1 154/4885 |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | HTR2B 3445/4885GBA1 3374/4885MMP1 2710/4885 |
| US-20190144429-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | HTR2B 3445/4885GBA1 3374/4885MMP1 2710/4885 |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | VIP, CTSC, PREP | HTR2B 3691/4885GBA1 796/4885MMP1 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.